Moderna Shares Rise Following Q3 Earnings Beat and Increased Full-Year Guidance
Moderna (MRNA) shares saw a recovery in premarket trading following the company's release of third-quarter results that exceeded analyst expectations. The biotech firm reported stronger performance driven primarily by higher-than-anticipated sales of its COVID-19 vaccines. In addition to the earnings beat, Moderna raised its full-year growth outlook, signaling confidence in its revenue trajectory for the remainder of the year. This positive momentum follows a recent 7% decline in share price during the previous trading session.
Tickers: $MRNA